Kellsye P. Fabian, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 8B13
- Bethesda, MD 20892
- 240-858-3465
- kellsye.fabian@nih.gov
RESEARCH SUMMARY
Dr. Fabian is an immunologist whose research interests involve cancer vaccines and the development of innovative combination therapies for the treatment of cancer. Her focus is on the strategic combination of multiple immuno-oncology agents that can engage, expand, enable, and evolve the immune response to provide therapeutic benefits in several tumor types. Her goal is to investigate novel immunotherapeutic approaches, such as cancer vaccines, immune checkpoint inhibitors, cell therapies, and immune-modulating agents to inform future clinical trials.
Areas of Expertise
Kellsye P. Fabian, Ph.D.
Research
Our research is focused on the development of novel recombinant vaccines and vaccine combination strategies. We aim to investigate and exploit immune mechanisms of novel anticancer agents to enhance vaccine efficacy and overall anti-tumor immune response. Specifically, we study how certain chemotherapeutic agents, small molecule targeted therapies, immune checkpoint inhibitors, cell therapies, and immune modulators alter the tumor and the tumor microenvironment to engage, expand, enhance, and enable anti-tumor T-cell and NK cell responses. We hypothesize that efficient tumor inhibition and survival benefits can be achieved through strategic combination of different immuno-oncology agents with diverse modalities.
Biography
Kellsye P. Fabian, Ph.D.
Dr. Fabian received her Ph.D. in Immunology from the University of Pittsburgh in 2017. She joined the Laboratory of Tumor Immunology and Biology (LTIB), Center for Cancer Research, NCI, NIH, as a Postdoctoral Fellow in 2017, and was appointed as a Staff Scientist in 2021. She is currently a Staff Scientist in the Center for Immuno-Oncology's Translational Research area. Her current research is on novel recombinant vaccines and vaccine strategies to further enhance anti-tumor T-cell and NK cell responses through strategic combination with chemotherapy, targeted small molecules, immune checkpoint inhibitors, cell therapy, and other novel immunotherapeutic agents that modulate the immune response.